Skip to main content

Table 2 Effects of pradigastat on fasting and postprandial triglyceride and apolipoprotein B48Data presented are geometric means (CV %), unless otherwise specified

From: Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

 

Baseline*

Treatment period 1

Treatment period 2

Treatment period 3

Pradigastat 20 mg (n = 6)

Pradigastat 40 mg (n = 6)

Pradigastat 10 mg (n = 4)

EOT

Ratio

EOT

Ratio

EOT

Ratio

Fasting TG, mmol/L

19.21 (35.2)

12.80. (25.0)

0.67. (33.1)

13.97. (79.2)

0.73. (47.7)

32.14. (35.8)

1.41. (26.9)

Peak PPTG, mmol/L

20.91. (27.0)

12.91. (29.4)

0.62. (27.8)

14.38. (84.9)

0.69. (71.8)

41.22. (34.1)§

1.69. (37.3)§

AUC0–9 PPTG, h*mmol/L

163.49. (29.3)

103.16. (22.7)

0.63. (25.1)

114.69. (79.7)

0.70. (65.8)

321.68. (36.5)§

1.63. (37.9)§

Fasting ApoB48, g/L

0.071. (51.3)

0.063. (41.6)

0.88. (25.5)

0.043. (67.1)

0.61. (37.0)

0.113. (47.5)

1.29. (23.2)

Peak PP ApoB48, g/L

0.079. (34.1)

0.067. (39.7)

0.84. (23.8)

0.048. (56.8)

0.61. (28.6)

0.149. (29.7)§

1.53. (20.0)§

AUC0–9 PP ApoB48, h*g/L

0.632. (36.2)

0.527. (39.9)

0.83. (22.1)

0.378. (63.1)

0.60. (33.3)

1.261. (30.7)§

1.60. (16.2)§

  1. ApoB48 = apolipoprotein B48; AUC0–9 = area under curve over 0 to 9 hours; CV = coefficient of variation; EOT = end of treatment; PP = postprandial; TG = triglycerides.
  2. *Baseline values are at Day −1 for all the parameters, except for fasting TG and ApoB48 (mean of Day −1 and Day 1); EOT values are at Day 21 for all parameters, except for fasting TG and ApoB48 (mean of Day 21 and Day 22); Geometric mean ratio to baseline; §n = 3.